Anthem Biosciences’ ₹3,395 crore IPO has been fully subscribed by July 15, 2025, driven by strong demand from Non-Institutional Investors and Retail Investors. The Bengaluru-based biotech company focuses on innovation-led contract research, development, and manufacturing services and is set to list its shares on July 21, 2025.
Bengaluru-based Anthem Biosciences Ltd, a leading Contract Research, Development and Manufacturing Organization (CRDMO), achieved full subscription for its Initial Public Offering (IPO) by July 15, 2025. The ₹3,395 crore issue was subscribed 1.15 times by the second day of bidding, according to data from the National Stock Exchange (NSE).
Anthem Biosciences operates in the biotech space with innovation-driven, technology-focused solutions across drug discovery, development, and manufacturing. It also produces advanced fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
The IPO has attracted notable attention from Non-Institutional Investors (NIIs), who subscribed 2.82 times their allotted quota. The Retail Individual Investors (RIIs) followed closely with an 89% subscription, while Qualified Institutional Buyers (QIBs) showed 38% subscription levels as of 11:00 a.m. on July 15.
The offering includes a price band of ₹540–₹570 per share and is set to close on July 16, 2025. Prior to the public bidding, Anthem Biosciences raised ₹1,016 crore from anchor investors.
Market analysts tracking grey market activities have reported a Grey Market Premium (GMP) of ₹116, indicating a 20.35% potential listing gain. The shares are scheduled to be listed on the NSE and BSE on July 21, with the allotment finalization expected by July 17.
Investors are closely watching the listing performance, especially amid growing interest in the Indian biotech and pharmaceutical manufacturing space.
